Biohaven CEO Vlad Coric finally had the attention of the FDA, and most importantly, Commissioner Marty Makary. In late April, after the company’s spinocerebellar ataxia drug had been rejected last year, Coric had won a meeting with the commissioner’s office to talk about a path forward for the rare disease drug... |
